eFFECTOR Therapeutics, Inc. (EFTR)
Develops cancer drugs that block proteins cancer cells need to survive.
$0.00+3.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+300.0%
The outlook
EFTR is trading near its 52-week low, sitting just 6% above that floor. The stock is currently above both its 50- and 200-day moving averages, showing a positive short-term trend. Analyst coverage appears thin, with the overall sentiment neutral.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Market cap
$3,763
52-wk high
$0.01
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—